Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

ry. Net income for the same period of 2009 included $126,000 of interest and financing expenses, $93,000 of interest and other income, and $482,000 of income tax expenses. Net loss attributable to shareholders for first quarter of 2010 was $307,000, or $0.01 loss per diluted share, as compared to net income attributable to shareholders of $25,000, or $0.00 per diluted share, in the same period of 2009.

As of March 31, 2010, Sinovac's cash and cash equivalents totaled $118.9 million, compared to $75.0 million as of December 31, 2009. The increase in cash and cash equivalents primarily reflects the contribution of approximately $62.0 million in net proceeds from the public offering of common shares, which closed in February 2010.

Recent Developments

Sinovac's 30%-owned joint venture, Sinovac Dalian, submitted an application to the SFDA to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac has filed a clinical trial application, but also the first candidate from the joint venture's pipeline for which a clinical trial application has been submitted to and accepted by the SFDA since the formation of the joint venture in January 2010.

After receiving regulatory approval from China's State Administration of Foreign Exchange, Sinovac Biotech, through it
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... , Sept. 30, 2014 CORD:USE Cord ... to announce that it has entered into an Equity ... (Tianhe) which has licensed a series of patented technologies for ... for possible clinical applications.  Tianhe is performing Phase I/II ... Spain using Tianhe,s Stem Cell ...
(Date:9/30/2014)... Angeles, CA (PRWEB) September 30, 2014 ... (EWS), the high-speed, chemical-free process to clean up large ... to shareholders, CEO Riggs Eckelberry reported on the launch ... Texas, at a site provided by partner STW ... up to 1000 barrels per day (bpd) and achieved ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... in developing a new material using nano-sized magnets that could ... capacity than is currently feasible, in a study published today ... modern data storage devices, like hard disk drives, rely on ... sections, but their overall design is limited by the way ...
... mobile bio-containment laboratory is now stationed in the Mexican ... The US-built lab provides new early warning capabilities for ... kind in Latin America. (Photo:  http://photos.prnewswire.com/prnh/20120329/FL78689 ... of technology being utilized on the front lines of ...
... Marshall Hicks, M.D., FSIR, an interventional radiologist and ... University of Texas MD Anderson Cancer Center in Houston, ... of Interventional Radiology during its 37th Annual Scientific Meeting ... of nearly 5,000 scientists and allied health professionals dedicated ...
Cached Biology Technology:Honeycombs of magnets could lead to new type of computer processing 2Honeycombs of magnets could lead to new type of computer processing 3US Lab Deployed to Boost Mexico's Response to Outbreaks of Infectious Disease 2Society of Interventional Radiology Names Marshall Hicks, M.D., FSIR, as 2012-13 President 2Society of Interventional Radiology Names Marshall Hicks, M.D., FSIR, as 2012-13 President 3
(Date:9/30/2014)... JOLLAJoseph Ecker, a Salk professor and Howard Hughes ... scientist, have been named recipients in the 2014 ... Health (NIH) through the BRAIN (Brain Research through ... neuroscience. The grant, announced September 30, provides more ... scientists over three years. , The BRAIN Initiative, ...
(Date:9/30/2014)... reports positive results of a phase 1 clinical ... lung cancer marked by rearrangement of the gene ROS1. ... non-small cell lung cancer testing positive for ROS1 gene ... complete responses and 33 partial responses. Median progression-free survival ... resume its growth after being slowed by treatment ...
(Date:9/30/2014)... urban and farm runoff in Hawaii is causing tumors ... , The study, published Tuesday in the peer-reviewed open-access ... runoff ends up in algae that the turtles eat, ... flippers and internal organs. , Scientists at Duke University, ... Atmospheric Administration (NOAA) conducted the study to better understand ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... Institute (Germany) and the ESRF have just discovered the ... bone by studying it with the synchrotron X-rays. This ... The hierarchical structure of bones makes them able to ... essentially rigid units at the molecular level. The re-sults ...
... of California, San Diego have discovered that the presence of ... fly (which glow at center due to a fluorescent protein) ... of its 800 unit eyes, an evolutionary change to an ... visual acuity and angular sensitivity. In contrast, beetles (shown surrounding ...
... By sampling different ocean locations for the presence of ... gained new insight into the dwelling places of the ... The symbiosis between special algal species and reef corals ... complex ecosystem, but our understanding of how this symbiosis ...
Cached Biology News:Bones at the nanoscale 2Ocean sampling yields environmental sources of coral symbionts 2
Mouse Anti-Human Kallikrein 2 (Hk2)...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Biology Products: